Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
Levi &amp; Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Forecasting The Future: 44 Analyst Projections For Sarepta Therapeutics
 
Via Benzinga
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why
Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal. 
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
What's Going On With Sarepta Shares Thursday?
 
Via Benzinga
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
From Sarepta Therapeutics, Inc.
Via Business Wire
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 
Via Stocktwits
Topics Death
SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders of the Pending Lead Plaintiff Deadline in the Securities Class Action Against SRPT
From Robbins LLP
Via GlobeNewswire
August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
August 25, 2025 Deadline: Contact Levi &amp; Korsinsky to Join Class Action Suit Against SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
From Bernstein Liebhard LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.